Company intelligence / Profile preview
Tasly Holding Group
Tianjin, China
- Ownership
- Private
- Employees
- ~15000
- Development stage
- Other
01
Overview
Tasly has completed Phase III trials for T89 in chronic stable angina (ORESA study ongoing) and has IND approval for TSL1502 in oncology; multiple biosimilars and herbals in Phase 3 or pending.
- Therapeutic areas
- EndocrinologyCardiovascularNeurologyPulmonologyOncology
- Modalities
- Small moleculeHerbalAntibody-drug conjugateBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Herbalife Nutrition (joint venture HT Innovations)Sutro Biopharma (license for STRO-002)AP Biosciences (license for bispecific antibodies AP201, AP505, AP116)SemBioSys Genetics
Beyond the preview
Go deeper on Tasly Holding Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tasly Holding Group.